Methyl Ergometrine Maleate is indicated for the prevention and treatment of postpartum hemorrhage due to uterine atony or subinvolution. It is typically administered after delivery of the baby but before delivery of the placenta.

Intramuscularly & Intravenously: 1 mL, 0.2 mg, after delivery of the anterior shoulder, after delivery of the placenta, or during the puerperium. May be repeated as required, at intervals of 2 to 4 hours.

Orally: One tablet, 0.2 mg, 3 or 4 times daily in the puerperium for a maximum of 1 week.

Common adverse reactions associated with Methyl Ergometrine Maleate may include-

• nausea
• vomiting
• headache
• increased blood pressure

Nausea

Vomiting

Headache

Hypertension (High Blood Pressure)

• Hypertension: Methyl Ergometrine Maleate may cause a significant increase in blood pressure. Use with caution in patients with hypertension and monitor blood pressure closely during administration.
• Uterine Hypertonicity: Excessive uterine contractions may occur. Carefully monitor uterine activity and discontinue if hypertonicity persists.
• Hypersensitivity: Cases of hypersensitivity reactions, including anaphylaxis, have been reported. Be prepared to manage allergic reactions promptly.